World Journal of Nuclear Medicine

EDITORIAL
Year
: 2019  |  Volume : 18  |  Issue : 2  |  Page : 123--126

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma


S Dizdarevic1, M Tulchinsky2, VR McCready1, J Mihailovic3, S Vinjamuri4, JR Buscombe5, ST Lee6, S Frangos7, M Sathekge8, Q Siraj9, P Choudhury10, H Bom11, M Franceschi12, A Ugrinska13, D Paez14, R Hussain15, J Mailman16, M Luster17, I Virgolini18, On behalf of the WARMTH Thyroid Group20 
1 Department of Imaging and Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton and Sussex Medical School, Royal Sussex County Hospital, Brighton, UK
2 Radiology Department, Nuclear Medicine Section, Penn State University, Milton S. Hershey Medical Center, USA
3 Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
4 Department of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UK
5 Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UK
6 Department of Molecular Imaging and Therapy, Austin Health, Melbourne; Olivia Newton-John Cancer Research Institute, Heidelberg, Australia School of Cancer Medicine, La Trobe University, Heidelberg, Australia
7 Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprus
8 Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa
9 Department of Nuclear Medicine, Farwania Hospital, Kuwait
10 Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
11 Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea
12 Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia
13 Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
14 Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria
15 Nuclear Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB)
16 World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA
17 Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany
18 Department of Nuclear Medicine, Medical University of Innsbruck, Austria

Correspondence Address:
S Dizdarevic
Department of Imaging and Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton and Sussex Medical School, Royal Sussex County Hospital, Brighton
UK




How to cite this article:
Dizdarevic S, Tulchinsky M, McCready V R, Mihailovic J, Vinjamuri S, Buscombe J R, Lee S T, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, Virgolini I, On behalf of the WARMTH Thyroid Group. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.World J Nucl Med 2019;18:123-126


How to cite this URL:
Dizdarevic S, Tulchinsky M, McCready V R, Mihailovic J, Vinjamuri S, Buscombe J R, Lee S T, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, Virgolini I, On behalf of the WARMTH Thyroid Group. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World J Nucl Med [serial online] 2019 [cited 2019 May 24 ];18:123-126
Available from: http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=2;spage=123;epage=126;aulast=Dizdarevic;type=0